## Contents

*Foreword*  
Preface  
*Contributors*

### Part I  History and Basic Principles

1. **Introduction to Drug Development and Regulatory Decision-Making**  
   *Lawrence J. Lesko and Chandrahass Sahajwalla*  
   1

   *Henry J. Malinowski and Agnes M. Westelinck*  
   13

3. **Regulatory Bases for Clinical Pharmacology and Biopharmaceutics Information in a New Drug Application**  
   *Mehul Mehta and John Hunt*  
   35

4. **New Drug Application Content and Review Process for Clinical Pharmacology and Biopharmaceutics**  
   *Chandrahass Sahajwalla, Veeneta Tandon, and Vanitha J. Sekar*  
   71
## Part II  In Vitro/ Pre-Clinical

5. In-vitro Drug Metabolism Studies During Development of New Drugs  
*Anthony Y. H. Lu and Shiew-Mei Huang*  
Page 87

6. Drug Transporters  
*Xiaoxiong Wei and Jashvant D. Unadkat*  
Page 111

7. Principles, Issues, and Applications of Interspecies Scaling  
*Iftekhar Mahmood*  
Page 137

## Part III  Clinical Pharmacology

8. Analytical Method Validation  
*Brian P. Booth and W. Craig Simon*  
Page 165

*Maria Sunzel*  
Page 187

10. Surrogate Markers in Drug Development  
*Jürgen Venitz*  
Page 213

11. Population Pharmacokinetic and Pharmacodynamic Analysis  
*Jogarao V. S. Gobburu*  
Page 229

12. Scientific and Regulatory Considerations for Studies in Special Population  
*Chandrahas Sahajwalla*  
Page 245

13. Conducting Clinical Pharmacology Studies in Pregnant and Lactating Women  
*Kathleen Uhl*  
Page 267

*Patrick J. Marroum, Hilde Spahn-Langguth, and Peter Langguth*  
Page 297

15. Assessing the Effect of Disease State on the Pharmacokinetics of the Drug  
*Marie Gårdmark, Monica Edholm, Eva Gil-Berglund, Carin Bergquist, and Tomas Salmonson*  
Page 345
### Contents

16. Clinical Pharmacology Issues Related to Specific Drug Classes During Drug Development 373  
   *Kellie Schoolar Reynolds, Vanitha J. Sekar, and Suresh Doddapaneni*

#### Part IV  Biopharmaceutics

17. Issues in Bioequivalence and Development of Generic Drug Products 399  
   *Barbara M. Davit and Dale P. Conner*

18. Regulatory Considerations for Oral Extended Release Dosage Forms and in vitro (Dissolution) in vivo (Bioavailability) Correlations 417  
   *Ramana S. Uppoor and Patrick J. Marroum*

19. In vivo Bioavailability Bioequivalence Waivers 449  
   *Patrick J. Marroum, Ramana S. Uppoor, and Mehul U. Mehta*

20. Bioavailability and Bioequivalence Issues for Drugs Administered via Different Routes of Administration: Inhalation/Nasal Products; Dermatological Products, Suppositories 475  
   *Edward D. Bashaw*

#### Part V  Contemporary and Special Interest Topics

21. Scientific and Regulatory Issues in Development of Chiral Drugs 503  
   *Chandrahas Sahajwalla, Jyoti Chawla, and Indra K. Reddy*

22. A Regulatory View of Liposomal Drug Product Characterization 525  
   *Kofi Kami and Brian P. Booth*

23. Challenges in Drug Development: Biological Agents of Intentional Use 535  
   *Andrea Meyerhoff*

24. The Regulation of Antidotes for Nerve Agent Poisoning 543  
   *Russell Katz and Barry Rosloff*
25. Bioequivalence Assessment: Approaches, Designs, and Statistical Considerations
   Rabindra N. Patnaik

Index